The AI memory crunch is in the consumer aisle. The investor question is which of three companies has pricing power…
Day: August 29, 2026
ROIV Has Its First Approval. Now Comes the Harder Part.
Lisraya wins dermatomyositis, but a boxed warning, a larger patient pool than advertised, and Phase 3 readouts define what the…